



(51) International Patent Classification:

**C07K 16/00** (2006.01) **A61K 39/395** (2006.01)  
**C07K 16/10** (2006.01)

(21) International Application Number:

PCT/IB2017/058194

(22) International Filing Date:

20 December 2017 (20.12.2017)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

201621044139 23 December 2016 (23.12.2016) IN

(71) Applicant: **SERUM INSTITUTE OF INDIA PRIVATE LIMITED** [IN/IN]; 212/2, Off Soli Poonawalla Road, Hadapsar, Pune, Maharashtra 411 028 (IN).

(72) Inventors: **MHALASAKANT, Dhere Rajeev**; Serum Institute Of India Pvt Ltd., of 212/2, Off Soli Poonawalla Road, Hadapsar, Pune, Maharashtra 411 028 (IN). **SHANKAR, Pisal Sambhaji**; Serum Institute Of India Pvt Ltd., of 212/2, Off Soli Poonawalla Road, Hadapsar, Pune, Maharashtra 411 028 (IN). **REDDY, Peddi Reddy Srinivas**; Serum Institute Of India Pvt Ltd., of 212/2, Off Soli Poonawalla Road, Hadapsar, Pune, Maharashtra 411 028 (IN).


vas; Serum Institute Of India Pvt Ltd., of 212/2, Off Soli Poonawalla Road, Hadapsar, Pune, Maharashtra 411 028 (IN). **CHAHAR, Singh Digamber**; Serum Institute Of India Pvt Ltd., of 212/2, Off Soli Poonawalla Road, Hadapsar, Pune, Maharashtra 411 028 (IN). **RAVINDRA, Yeolekar Leena**; Raviraj, 7B Anurekha Society, Nav Sahyadri, Karve Nagar, Pune 411052 (IN). **SINGH, Chouhan Pankaj**; Serum Institute Of India Pvt Ltd., of 212/2, Off Soli Poonawalla Road, Hadapsar, Pune, Maharashtra 411 028 (IN). **DATTATRAY, Avalaskar Nikhil**; Serum Institute Of India Pvt Ltd., of 212/2, Off Soli Poonawalla Road, Hadapsar, Pune, Maharashtra 411 028 (IN).

(74) Agent: **GARG, Vidisha** et al.; Anand and Anand Advocates, B-41, Nizamuddin East, New Delhi 110013 (IN).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,

(54) Title: IMPROVED METHODS FOR ENHANCING ANTIBODY PRODUCTIVITY IN MAMMALIAN CELL CULTURE AND MINIMIZING AGGREGATION DURING DOWNSTREAM, FORMULATION PROCESSES AND STABLE ANTIBODY FORMULATIONS OBTAINED THEREOF

Figure 1 : Flow chart - Downstream processing for purification of monoclonal antibody



(57) Abstract: The invention, describes an efficient platform for antibody manufacturing and formulation, that provides i) cell culture process with improved feeding strategy resulting in high antibody titer between 2 gm/L to 5 gm/L; ii) improved purification process showing optimal percentage recovery, high purity monomer content, minimum aggregation/particulate formation, minimum impurity levels; and iii) high concentration stable liquid formulation with optimal osmolality and low viscosity across different temperature excursions and devoid of aggregation. The preferred antibodies include IgG1 monoclonal antibody specific to the Dengue virus epitope in domain III of the E protein and IgG1 monoclonal antibody specific to the rabies virus surface G glycoprotein.

[Continued on next page]

OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

**(84) Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

**Declarations under Rule 4.17:**

— *of inventorship (Rule 4.17(iv))*

**Published:**

— *with international search report (Art. 21(3))*